Your browser is no longer supported. Please, upgrade your browser.
EYEN Eyenovia, Inc. monthly Stock Chart
EYEN [NASD]
Eyenovia, Inc.
Index- P/E- EPS (ttm)-1.86 Insider Own2.00% Shs Outstand11.74M Perf Week-1.68%
Market Cap54.94M Forward P/E- EPS next Y-1.63 Insider Trans- Shs Float6.97M Perf Month-4.49%
Income-19.80M PEG- EPS next Q-0.43 Inst Own10.90% Short Float1.69% Perf Quarter-15.52%
Sales- P/S- EPS this Y-252.60% Inst Trans16.90% Short Ratio2.23 Perf Half Y50.97%
Book/sh1.05 P/B4.46 EPS next Y8.40% ROA-97.20% Target Price17.00 Perf Year-41.50%
Cash/sh1.22 P/C3.84 EPS next 5Y- ROE-108.80% 52W Range2.40 - 8.31 Perf YTD64.21%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-43.67% Beta-
Dividend %- Quick Ratio5.90 Sales past 5Y- Gross Margin- 52W Low95.00% ATR0.34
Employees22 Current Ratio5.90 Sales Q/Q- Oper. Margin- RSI (14)36.03 Volatility7.83% 6.44%
OptionableNo Debt/Eq0.00 EPS Q/Q-9.70% Profit Margin- Rel Volume0.75 Prev Close4.77
ShortableYes LT Debt/Eq0.00 EarningsMay 14 BMO Payout- Avg Volume52.93K Price4.68
Recom1.40 SMA20-6.66% SMA50-16.67% SMA2004.32% Volume39,933 Change-1.90%
Jun-04-19 08:30AM  Eyenovia Enrolls First Patient in Phase III CHAPERONE Study for Progressive Myopia GlobeNewswire
May-14-19 06:30AM  Eyenovia Reports First Quarter 2019 Financial Results GlobeNewswire -15.11%
May-06-19 10:53AM  Introducing Eyenovia (NASDAQ:EYEN), The Stock That Dropped 33% In The Last Year Simply Wall St.
May-01-19 08:30AM  Eyenovia Announces Conference Call and Webcast for First Quarter 2019 Financial Results GlobeNewswire +5.35%
Mar-27-19 06:30AM  Eyenovia Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Mar-13-19 08:30AM  Eyenovia Announces Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results GlobeNewswire
Mar-04-19 08:30AM  Eyenovia to Participate in Two Upcoming Investor Conferences GlobeNewswire
Feb-25-19 08:30AM  Eyenovia Announces Confirmatory Results from Second MicroStat Phase III Registration Study for Mydriasis GlobeNewswire +5.04%
Feb-13-19 08:30AM  Eyenovia confirms expanded MicroProst Phase III indication to enroll broad patient population for IOP lowering GlobeNewswire
Feb-06-19 08:30AM  Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia GlobeNewswire +13.64%
Feb-05-19 08:00AM  Biotech Stocks to Watch ACCESSWIRE +7.18%
Jan-31-19 08:30AM  Biotechs Investors Are Flocking To ACCESSWIRE +6.38%
Jan-30-19 09:35AM  4 Healthcare Stocks Raising The Bar On Wednesday (1/30/19) ACCESSWIRE +25.10%
07:56AM  Eyenovia shares rocket on positive results in trial of device used to cause dilation of the eye MarketWatch
07:00AM  Eyenovia Announces Positive Results in the MicroStat MIST-1 Phase III Registration Study for Mydriasis GlobeNewswire
Dec-25-18 01:39PM  Do Institutions Own Eyenovia, Inc. (NASDAQ:EYEN) Shares? Simply Wall St.
Dec-19-18 02:45PM  4 Healthcare Stocks to Watch on Wednesday (12/19/18) ACCESSWIRE
09:05AM  Eyenovia Prices Public Offering of Common Stock GlobeNewswire
Dec-03-18 09:00AM  Eyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Study GlobeNewswire +18.77%
Nov-28-18 04:05PM  Eyenovia Announces Publication of its PG21 Phase II Trial Results Demonstrating Robust IOP Lowering Effect and Patient Usability GlobeNewswire
Nov-27-18 10:44AM  Eyenovia Initiates Phase III Study for Mydriasis Candidate Zacks +11.11%
07:32AM  The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial Benzinga
Nov-26-18 05:26PM  Eyenovia Initiates Phase III MicroStat Program for Pharmacologic Mydriasis: Enrolls First Patient in MIST-1 Study PR Newswire +10.77%
09:00AM  Eyenovia Initiates Phase III MicroStat Program for Pharmacologic Mydriasis: Enrolls First Patient in MIST-1 Study GlobeNewswire
Nov-21-18 08:50AM  Market Trends Toward New Normal in Wilhelmina International, Eyenovia, aTyr Pharma, Avinger, Viacom, and Axsome Therapeutics Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire -6.99%
Nov-13-18 07:30AM  Eyenovia Announces FDA Acceptance of MicroStat IND Application for Mydriasis GlobeNewswire -15.38%
06:30AM  Eyenovia Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-01-18 08:30AM  Eyenovia Announces Conference Call and Webcast for Third Quarter 2018 Financial Results GlobeNewswire
Oct-23-18 09:00AM  Eyenovia to Present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology 2018 GlobeNewswire
Oct-05-18 08:01PM  Johnson Fistel Announces Investigations of PPDAI Group Inc., Menlo Therapeutics Inc., Eyenovia, Inc. and Dragon Victory International Limited; Investors with Losses Encouraged to Contact Firm PR Newswire
Sep-24-18 07:22PM  Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating Possible Securities Fraud Violations by Certain Officers and Directors of Menlo Therapeutics, Hill International, and Eyenovia on Behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire -8.31%
Sep-19-18 08:30AM  Eyenovia to Participate in Panel Presentation at OSN New York 2018 GlobeNewswire
Sep-18-18 07:30AM  Eyenovia to Present at the Ladenburg Thalmann 2018 Healthcare Conference GlobeNewswire
Sep-12-18 05:47PM  Lifshitz & Miller LLP Announces Investigation of Altice USA, Inc., Dun & Bradstreet, Eyenovia, Inc., K2M Group Holding, Inc., KMG Chemicals, Inc., LifePoint Health, Inc., Reis, Inc., and Zoe's Kitchen, Inc. PR Newswire
Sep-06-18 06:40AM  Eyenovia Sees Hammer Chart Pattern: Time to Buy? Zacks
Aug-21-18 07:30AM  Eyenovia to Present at the 20th Annual H.C. Wainwright Global Investment Conference GlobeNewswire
05:35AM  Eyenovia Sees Hammer Chart Pattern: Time to Buy? Zacks
Aug-17-18 03:39PM  Bragar Eagel & Squire, P.C. is Investigating Eyenovia, Inc. (EYEN) on Behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire
Aug-16-18 02:07PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Eyenovia, Inc. (EYEN) PR Newswire
01:43PM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Eyenovia, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
Aug-15-18 06:56PM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Eyenovia, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
04:30PM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Eyenovia, Inc. EYEN Business Wire
Aug-14-18 06:30AM  Eyenovia, Inc. to Host Earnings Call ACCESSWIRE
06:30AM  Eyenovia Reports Second Quarter 2018 Financial Results GlobeNewswire
Aug-13-18 08:30AM  Eyenovias EYN PG21 Trial Evaluating High-Precision Microdose of Latanoprost Demonstrates Robust Intraocular Pressure Lowering and Patient Usability GlobeNewswire
Aug-02-18 03:55PM  EYENOVIA, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Eyenovia,Inc. for potential violation of securities laws ACCESSWIRE
Jul-31-18 08:30AM  Eyenovia Announces Conference Call and Webcast for Second Quarter 2018 Financial Results GlobeNewswire
Jul-09-18 07:30AM  Eyenovia Appoints Michael Rowe as Vice President of Marketing Ahead of Initiation of Multiple Phase III Programs GlobeNewswire +15.97%
Jun-11-18 07:30AM  Eyenovia to Present at the JMP Securities 2018 Life Sciences Conference GlobeNewswire
Jun-05-18 09:13PM  Glancy Prongay & Murray LLP Continues Investigation on Behalf of Eyenovia, Inc. Investors (EYEN) Business Wire
07:30AM  Eyenovia Receives Notices of Allowance from USPTO on Two Additional Patent Applications for Ophthalmic Drug Delivery GlobeNewswire
May-21-18 07:10AM  Wired News EU Approved Exelixis/Ipsens CABOMETYX in Europe for Intermediate - or Poor-Risk Advanced Renal Cell Carcinoma ACCESSWIRE
May-09-18 06:30AM  Eyenovia Reports First Quarter 2018 Financial Results and Completion of EYN PG21 Study GlobeNewswire
Apr-24-18 07:44AM  Eyenovia, Inc. (EYEN) Sees Hammer Chart Pattern: Time to Buy? Zacks
Apr-19-18 08:30AM  Eyenovia Announces Conference Call and Webcast for First Quarter 2018 Financial Results GlobeNewswire
Apr-03-18 08:31PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Eyenovia, Inc. Investors (EYEN) Business Wire
Apr-02-18 06:30AM  Eyenovia Announces Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Mar-26-18 04:05PM  Eyenovia Appoints Three Industry Veterans to Board of Directors GlobeNewswire
Mar-19-18 08:30AM  Eyenovia Announces Conference Call and Webcast for Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Feb-27-18 08:30AM  Eyenovia to Present at the 30th Annual ROTH Conference GlobeNewswire
Feb-21-18 08:30AM  Eyenovia Advances MicroPine for Myopia into Phase III Clinical Development and Appoints Stanford Professor Dr. Douglas Fredrick to its Scientific Advisory Board and Myopia Program Steering Committee GlobeNewswire
Jan-29-18 04:05PM  Eyenovia Announces Closing of $27.3 Million Initial Public Offering GlobeNewswire
Jan-25-18 06:30AM  Eyenovia Announces Pricing of Initial Public Offering GlobeNewswire
Eyenovia, Inc., a clinical stage ophthalmic biopharmaceutical company, engages in developing a pipeline of microdose therapeutics in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma, open angle glaucoma, and ocular hypertension; MicroStat, which has completed Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of hyperemia, pruritis, and dry eye; and MicroPine for the treatment of progressive myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.